Diego Francisco Márquez, Alberto Ortiz, Daniel González-Moreno, Luis Miguel Ruilope, Gema Ruiz-Hurtado
{"title":"Finerenone: Evidence for benefit in Early Stages of Cardiovascular-Kidney-Metabolic Syndrome.","authors":"Diego Francisco Márquez, Alberto Ortiz, Daniel González-Moreno, Luis Miguel Ruilope, Gema Ruiz-Hurtado","doi":"10.1159/000548494","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular-kidney-metabolic (CKM) syndrome is a recently introduced concept that links chronic kidney disease (CKD), cardiovascular disease (CVD), and metabolic risk factors such as obesity or diabetes mellitus (DM). The use of eGFR <60 mL/min/1.73 m² as a CKD indicator often detects more advanced stages of renal disease, even though risk is present at earlier stages, particularly in the presence of albuminuria.</p><p><strong>Summary: </strong>The non-steroidal mineralocorticoid receptor antagonist finerenone has demonstrated efficacy in reducing cardiovascular and renal outcomes in patients with CKD and type 2 DM. Data from FIDELITY, a pooled analysis of FIDELIO-DKD and FIGARO-DKD, showed significant reductions in kidney failure and cardiovascular outcomes in patients with CKD and type 2 DM. Moreover, data from FINEARTS-HF trial revealed that finerenone prevents onset of albuminuric CKD in patients.</p><p><strong>Key messages: </strong>These results support a paradigm shift toward earlier intervention in CKM syndrome, with the aim of preserving renal function. Finerenone holds promise for changing the trajectory of CKD within a broader CKM framework. Ongoing trials will further define its role in diverse patient populations and stages of CKM syndrome.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"1-15"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000548494","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cardiovascular-kidney-metabolic (CKM) syndrome is a recently introduced concept that links chronic kidney disease (CKD), cardiovascular disease (CVD), and metabolic risk factors such as obesity or diabetes mellitus (DM). The use of eGFR <60 mL/min/1.73 m² as a CKD indicator often detects more advanced stages of renal disease, even though risk is present at earlier stages, particularly in the presence of albuminuria.
Summary: The non-steroidal mineralocorticoid receptor antagonist finerenone has demonstrated efficacy in reducing cardiovascular and renal outcomes in patients with CKD and type 2 DM. Data from FIDELITY, a pooled analysis of FIDELIO-DKD and FIGARO-DKD, showed significant reductions in kidney failure and cardiovascular outcomes in patients with CKD and type 2 DM. Moreover, data from FINEARTS-HF trial revealed that finerenone prevents onset of albuminuric CKD in patients.
Key messages: These results support a paradigm shift toward earlier intervention in CKM syndrome, with the aim of preserving renal function. Finerenone holds promise for changing the trajectory of CKD within a broader CKM framework. Ongoing trials will further define its role in diverse patient populations and stages of CKM syndrome.
期刊介绍:
The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.